JP2011505336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011505336A5 JP2011505336A5 JP2010532071A JP2010532071A JP2011505336A5 JP 2011505336 A5 JP2011505336 A5 JP 2011505336A5 JP 2010532071 A JP2010532071 A JP 2010532071A JP 2010532071 A JP2010532071 A JP 2010532071A JP 2011505336 A5 JP2011505336 A5 JP 2011505336A5
- Authority
- JP
- Japan
- Prior art keywords
- azacytidine
- pharmaceutical composition
- composition according
- aza
- deoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98463807P | 2007-11-01 | 2007-11-01 | |
| US99278107P | 2007-12-06 | 2007-12-06 | |
| US3409308P | 2008-03-05 | 2008-03-05 | |
| US8606908P | 2008-08-04 | 2008-08-04 | |
| US9085208P | 2008-08-21 | 2008-08-21 | |
| PCT/US2008/012430 WO2009058394A1 (en) | 2007-11-01 | 2008-11-03 | Cytidine analogs for treatment of myelodysplastic syndromes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011505336A JP2011505336A (ja) | 2011-02-24 |
| JP2011505336A5 true JP2011505336A5 (enExample) | 2011-12-22 |
Family
ID=40367738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010532071A Pending JP2011505336A (ja) | 2007-11-01 | 2008-11-03 | 骨髄異形成症候群治療のためのシチジンアナログ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100311683A1 (enExample) |
| EP (1) | EP2211870A1 (enExample) |
| JP (1) | JP2011505336A (enExample) |
| CA (1) | CA2742252A1 (enExample) |
| WO (1) | WO2009058394A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US6943249B2 (en) * | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| US6887855B2 (en) | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US8969372B2 (en) | 2003-11-14 | 2015-03-03 | Aptose Boisciences Inc. | Aryl imidazoles and their use as anti-cancer agents |
| ES2774226T3 (es) | 2008-05-15 | 2020-07-17 | Celgene Corp | Formulaciones orales de análogos de citidina y métodos de uso de los mismos |
| CA2789365A1 (en) | 2009-02-10 | 2010-08-19 | Celgene International Sarl | Methods for treating non-small cell lung cancer using 5-azacytidine |
| US9951098B2 (en) | 2011-03-31 | 2018-04-24 | Pharmion Llc | Synthesis of 5-azacytidine |
| WO2013022872A1 (en) * | 2011-08-10 | 2013-02-14 | Celgene Corporation | Gene methylation biomarkers and methods of use thereof |
| BR112014010417A2 (pt) | 2011-11-01 | 2014-11-18 | Celgene Corp | Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina |
| JP6231988B2 (ja) | 2011-11-03 | 2017-11-15 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｎｅｄｄ８活性化酵素阻害剤および低メチル化剤の投与 |
| US9493500B2 (en) * | 2012-07-19 | 2016-11-15 | Richard Daifuku | Fluorinated pyrimidine analogs and methods of use thereof |
| CA2906284A1 (en) * | 2013-03-15 | 2014-09-18 | Epigenetics Pharma Llc | Fluorinated pyrimidine analogs and methods of use thereof |
| CN105764511B (zh) | 2013-10-04 | 2019-01-11 | 艾普托斯生物科学公司 | 用于治疗癌症的组合物和方法 |
| SMT202300081T1 (it) | 2014-08-22 | 2023-05-12 | Celgene Corp | Metodi di trattamento di mieloma multiplo con composti immunomodulatori in combinazione con anticorpi |
| JP2019506434A (ja) * | 2016-02-26 | 2019-03-07 | エピジェネティクス・ファーマ・エルエルシー | ２’，２’−ジフルオロ−５−アザ−２’−デオキシシチジンまたはそれらのプロドラッグを有するｔｐ５３野生型腫瘍の治療方法 |
| WO2017189647A1 (en) * | 2016-04-26 | 2017-11-02 | Memorial Sloan Kettering Cancer Center | Methods and compositions for the treatment of myelodysplastic syndrome |
| JP2021501203A (ja) | 2017-10-30 | 2021-01-14 | アプトース バイオサイエンシズ インコーポレイテッド | がん治療用のアリールイミダゾール |
| GB201917899D0 (en) * | 2019-12-06 | 2020-01-22 | Nanexa Ab | New composition |
| CA3199623A1 (en) * | 2020-10-27 | 2022-05-05 | Vor Biopharma Inc. | Compositions and methods for treating hematopoietic malignancy |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641758A (en) * | 1993-11-10 | 1997-06-24 | Kluge; Michael | Cytarabine derivatives, the preparation and use thereof |
| US6096757A (en) * | 1998-12-21 | 2000-08-01 | Schering Corporation | Method for treating proliferative diseases |
| TR200102688T2 (tr) * | 1999-03-18 | 2002-01-21 | Celgene Corporation | İkameli 1-okso ve 1,3-dioksoizoindolinler ve enflamatuar sitokin seviyelerinin azaltılması için farmasötik bileşimlerde kullanımları. |
| DE60118571T2 (de) * | 2000-05-15 | 2007-02-01 | Celgene Corp. | Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten |
| US6905669B2 (en) * | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| CA2488013A1 (en) * | 2002-05-30 | 2003-12-11 | Celgene Corporation | Methods of using jnk or mkk inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| US7842691B2 (en) * | 2002-10-15 | 2010-11-30 | Celgene Corporation | Method for the treatment of myelodysplastic syndromes using cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-OXO-2,3-dihydro-1 H-isoindol-4-yl}-amide |
| EP1556010A4 (en) * | 2002-10-31 | 2007-12-05 | Supergen Inc | PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS |
| US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US20040152632A1 (en) * | 2002-11-06 | 2004-08-05 | Wyeth | Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome |
| US6887855B2 (en) * | 2003-03-17 | 2005-05-03 | Pharmion Corporation | Forms of 5-azacytidine |
| US6943249B2 (en) * | 2003-03-17 | 2005-09-13 | Ash Stevens, Inc. | Methods for isolating crystalline Form I of 5-azacytidine |
| WO2005110408A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
| CA2563207A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
| US20060128654A1 (en) * | 2004-12-10 | 2006-06-15 | Chunlin Tang | Pharmaceutical formulation of cytidine analogs and derivatives |
| US9180118B2 (en) * | 2006-07-18 | 2015-11-10 | University Of Rochester | Thiadiazolidinone derivatives |
| CA2661983C (en) * | 2006-08-30 | 2015-05-05 | Mount Sinai School Of Medicine Of New York University | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| WO2008028193A2 (en) * | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
| ES2774226T3 (es) * | 2008-05-15 | 2020-07-17 | Celgene Corp | Formulaciones orales de análogos de citidina y métodos de uso de los mismos |
-
2008
- 2008-11-03 US US12/740,636 patent/US20100311683A1/en not_active Abandoned
- 2008-11-03 EP EP08845256A patent/EP2211870A1/en not_active Withdrawn
- 2008-11-03 JP JP2010532071A patent/JP2011505336A/ja active Pending
- 2008-11-03 WO PCT/US2008/012430 patent/WO2009058394A1/en not_active Ceased
- 2008-11-03 CA CA2742252A patent/CA2742252A1/en not_active Abandoned